Skip to content
VisionSmart UK

Administering Pluripotent Cells in Utero to Infants with Spina Bifida Enhances Life Outcomes, Research Shows

A groundbreaking clinical study has found that providing pluripotent cells to unborn babies suffering from spina bifida as part of a surgical repair can be a "major milestone" in addressing congenital conditions.

Study Parameters and Security

The US-based trial involved six unborn babies with the 'open' form of spina bifida. Doctors administered regenerative cells sourced from the maternal placenta to the surface of the baby's spinal cord while the defect was being closed.

Importantly, the regenerative treatment was found to be safe. Researchers confirmed that the therapy did not induce tumors, interfere with wound healing, or impede the resolution of related neurological issues.

Encouraging Results

Magnetic resonance imaging performed on the newborns confirmed a complete reversal of hindbrain herniation in each of the babies. This favorable anatomical change is a key indicator for enhanced physical outcomes.

"If it makes a greater number of infants capable of walking who previously could not, then it would become the conventional approach," said the lead researcher. "The results are extremely promising and create a pathway toward a variety of prospective novel therapies."

Future Implications and Hope

Experts not involved in the trial have suggested that additional validation of these noted improvements could herald a "fresh chapter" in in-utero treatment. The potential to improve neurological damage occurring during fetal development is considered a paradigm-shifting aim.

Notably important would be advancements for continence and digestive health, which are typical difficulties for individuals living with this defect.

The Path Forward

While this initial trial was small in scale, its confirmed tolerability and hopeful trends provide a strong foundation for expanded clinical research. The integration of stem cell therapy with proven prenatal surgical methods holds considerable promise for improving the prognosis for infants diagnosed prenatally with myelomeningocele.

About the author

Megan Miller

A tech strategist with over a decade of experience in digital innovation and business transformation across European markets.

VisionSmart UK

Type to search articles.